V-Bio Ventures

V-Bio Ventures operates as a specialized life science Venture Capital fund, actively co-creating new ventures and investing in early- to mid-stage companies across Europe and beyond. The firm focuses on identifying and supporting businesses that leverage differentiated technology within the therapeutics space, including both drug discovery and development, aiming to address significant unmet medical needs. Their approach integrates capital provision with deep sector expertise, transforming scientific innovation into products with potential for societal impact.

The firm was co-founded in 2015 by Christina Takke and Willem Broekaert. Christina Takke brought over 15 years of experience in European Venture Capital, including a partnership role at Forbion Capital Partners. Willem Broekaert contributed more than 15 years in VC-backed life sciences as an entrepreneur and executive, along with a background as a professor in plant biotechnology. Their establishment of V-Bio Ventures stemmed from an insight into the potential of scientific advancements from institutions like the Flanders Institute for Biotechnology (VIB) to form viable commercial entities.

V-Bio Ventures targets companies developing innovative and transformative technologies with high potential to positively impact people’s lives. Its vision centers on investing in a healthier future by backing ventures that can successfully bring scientific breakthroughs to market. The firm seeks to become an integral part of the companies it supports, providing strategic guidance beyond mere capital to foster long-term success and realize the full potential of life science innovations.